What are the effects of Etrasimod-Velsipity tablets?

Itramod (Etrasimod) is a new oral sphingosine-1-phosphate (S1P) receptor modulator. In recent years, it has gradually received attention in the treatment of inflammatory bowel disease, especially moderate to severe active stage ulcerative colitis (UC) . Compared with traditional immunosuppressants or biological agents, the research and development concept of itrimod is more precise. It reduces lymphocytes from entering the colon inflammatory area by selectively regulating S1P1, S1P4 and S1P5 receptors, thereby reducing the inflammatory response. This mechanism enables it to effectively control symptoms clinically while avoiding the risks caused by broad-spectrum immunosuppression.

From the perspective of pharmacodynamic characteristics, itrimod shows significant potential in improving the clinical symptoms of ulcerative colitis. After taking the medicine, the incidence of diarrhea, bloody stools and abdominal discomfort can be improved in patients. Unlike some drugs that have a slower onset of action, itrimod has a faster time of action, with symptom relief observed within weeks in some studies, providing a new treatment option for patients in the acute active phase. At the same time, it is also believed to be able to help maintain long-term remission of the disease and reduce the risk of recurrence to a certain extent.

In addition, one of the great advantages of itrimod is its oral administration. Traditional biological agents such as anti-TNF-α drugs usually require intravenous infusion or subcutaneous injection, which has certain shortcomings in terms of compliance and convenience. Itrimod, as a once-daily oral small molecule drug, has greatly improved patients' acceptance and quality of life, and also made it of practical application value in the long-term management of chronic diseases.

It is worth noting that itrimod has shown good tolerance in clinical applications. Although some patients may experience mild adverse reactions, such as headache, bradycardia, or mild changes in liver function indicators, overall safety is relatively controllable. This is related to its selectivity for S1P receptors, which means it avoids excessive interference with S1P2, S1P3 and other receptors, thereby reducing the incidence of adverse events in the cardiovascular system or respiratory system.

Reference materials:https://www.drugs.com/mtm/etrasimod.html